RESUMO
Objective To investigate the expression of fibroblast growth factor-2 (FGF-2) and fibroblast growth factor receptor-4 ( FGFR-4 ) in the papillary thyroid carcinomas ( PTC ) and clinical significance . Methods Immunohistochemistry and Western blotting for the expression of FGF-2 and FGFR-4 were performed in 89 cases of PTC and 30 cases of normal thyroid tissues ( NTT) adjacent to the tumors .Results Immunohistochemistry results showed that , FGF-2 and FGFR-4 expressions were high in thyroid carcinoma (P0.05).Analyzed by Western blotting technique ,FGF-2 and FGFR-4 expressions in thyroid carcinoma were significantly higher than that in normal tissue ,with decrease of cancer degree of tissue differentiation and significantly up regulated expression (P<0.05).Expressions of FGF-2 and FGFR-4 were in a positive linear correlation in the disease (rs=0.434,P<0.01).Conclusion The expressions of FGF-2 and FGFR-4 are correlated with papillary thyroid cancer and they participated in the process of invasion and metastasis , both of which have a positive synergistic effect .The degree of malignancy and biological behavior are meaningful and comprehensive indicators ,which provide a theoretical basis for the subsequent experimental studies of cellular and molecular biology .
RESUMO
Objective To investigate the differences of related clinicopathologic features in colorectal cancer (CRC) patients with or without Type 2 Diabetes Mellitus (T2DM).Methods Using case-control studies,retrospective analysis of colorectal cancer of 60 patients with colorectal cancer hospitalization and 32 cases of T2DM were taken.The clinical data,histological grade,tumor size,clinical stage and lymph node metastasis pathology indicators conditions of the hospitalized CRC patients with or without type 2 diabetes were compared.Results The average age of the team with hospitalized CRC patients combined with type 2 diabetes is (64.90 ±8.87),fasting blood-glucose is (8.33 ±4.66) mmol/L.BMI and TG are (25.77 ±3.80) kg/m2 and (1.71 ±0.85) mmol/L which were all higher((54.70 ± 11.62),(5.85 ±0.88) mmol/L,(23.57 ±3.64)kg/m2,(1.33 ± 0.83) mmol/L) than patients without DM.There were significant differences between two groups (t =4.324,t =2.982,t =2.728,t =2.045,respectively,P ＜ 0.05).However,total cholesterol,high density lipoprotein-cholesterol and low density lipoprotein-cholesterol had no significantly differences with those patients without DM (P ＞ 0.05).There were no significant differences of clinicopathologic features between CRC patients with and without DM (P ＞ 0.05).Conclusion There is a certain correlation between CRC and DM,DM increases the risk of colorectal cancer so diabetes patients should be early screened for colorectal,with a view to early detection,treatment and improve the prognosis.
RESUMO
ObjectiveTo investigate the control rate and influence factors of glycolated hemoglobin A1C(HbA1c) of type 2 diabetes in Baoding city community.MethodsA cluster-randomized study was conducted and three communities were selected randomly.The study involved all of people aged 45 years old and above in the three communities.The type 2 diabetic patients diagnosed before,were recorded through the cross section study.Then the questionnaire was finished.All diabetic plasma HbA1c was determined by HPLC method.ResultsEighty-seven patients with HbA1c≤7％ were only 18.6％ in all diabetic patients.As the plasma level of HbA1c increased,occurrences of macroangiopathy and microangiopathy were both increased,by the trend test.Logistic regression analysis showed that therapeutic measures and knowledge about diabetes were main influence factors of achieving the hemoglobin Alc target of ＜7％ in type 2 diabetes.ConclusionThere were low HbA1c control in diabetic patients of Baoding community,and knowing diabetes well and receiving insulin treatment might decrease HbA1c level apparently.
RESUMO
HIC1 (hypermethylated in cancer 1) encodes a transcriptional repressor,and extensively resides in various kinds of normal tissue.HIC1 gene is located in chromosome 17p13.3,in which loss of heterozygote or super-methylation is frequently found in a variety of human cancers.As a new tumor marker,HIC1 has been confirmed down-regulated in a wide variety of solid cancers because of HIC1 promoter hypermethylation,and may be associated with tumor prognosis.As a tumor suppressor,HIC1 participates in the development of tumor process through various ways,and is involved in cell proliferation,tumour growth,and angiogenesis.Therefore,the abnormal hypermethylation or the loss of expression of HIC1 in tumor cells or abnormal function could be one of the important mechanisms of tumor development,and may become a new potential therapeutic targets for cancer.
RESUMO
Objective Toinvestigatetheexpressionof SIRT1anditsassociationwith clinicopathologic features in breast carcinoma with type 2 diabetes mellitus.MethodsThe expression of SIRT1 in 30 breast cancer with type 2 diabetes mellitus,65 samples of breast cancer without diabetes mellitus and 18 samples of corresponding normal breast tissues was investigated using immunohistochemistry.ResultsThe positive rate of SIRT1 in breast cancer tissues was significantly higher than that breast cancer with type 2 diabetes mellitus and normal breast tissue (P ＜0.05). In breast cancer with type 2 diabetes mellitus group.The positive rate of SIRT1 was significantly higher than that normal breast tissue(P ＜0.05).The expression of SIRT1 was positively correlated with the number of lymph node(P =0.011),pTNM tumor stage (P =0.028), p53 (P =0.003) and Her-2 (P =0.031) in breast cancer with type 2 diabetes mellitus group. The expression level of SIRT1 in lymph node-positive group was higher than that in lymph node-negative group (P ＜0.05).The expression level of SIRT1 was in lymph node-positive group was higher than that in lymph node-negative group(P ＜0.05).ConclusionSIRTI was up-regulated in breast cancer with type 2 diabetes mellitus,but its expression was lower than that breast cancer without diabetes mellitus,and was associated with the progression of diabetes mellitus. SIRT1 was positively correlated with lymph node, pTNM tumor stage,p53 and Her-2, SIRT1 may be a novel biological parameter to evaluate the malignant degree of breast carcinoma and to predict prognosis of breast cancer.
RESUMO
Objective To investigate differences of ctinicopathologic features in breast cancer patients with or without Type 2 Diabetes Mellitus(DM).Methods The general conditions and elinicopathologic features of the hospitalized breast cancer patients with or without type 2 diabetes were analyzed using a case-control study.Results The average age,fasting blood-glucose,BMI and TG were(58.4 ± 7.80),(8.15 ± 2.80)mmol/L,(27.72 ± 3.47)mmol/L and(2.36 ± 1.18)mmol/L in patients with DM,and(51.6 ± 9.90),(5.13 ±0.63)mmol/L,(24.15 ± 4.95)mmol/L and(1.32 ± 0.59)mmol/L in patients without DM.There were significantdifference between the two groups(t =2.968,P =0.004; t =5.757,P ＜ 0.001 ; t =3.235,P =0.002; t =4.330,P ＜0.001,respectively).HDL-C in patients with DM was(1.39 +0.20)mmol/L,which was significantly lower than that of(1.50 ± 0.24)mmol/L in patients without DM(t =2.000,P =0.05).TC and LDL-C was(4.89 ± 1.16)mmol/L and(3.02 ±0.90)mmol/L in patients with DM,which were not significantly different with those of(4.79 ±0.85)mmol/L and(2.97 +0.61)mmol/L in patients without DM(t =0.396,P =0.693,and t =0.255,P =0.800,respectively).More patients were in the menopausal status in breast cancer patients with Type 2 DM compared to the other group(x2 =11.835,P =0.001).The expression of Her-2 was 76.7％(23/30)in breast cancer patients with Type 2 DM,which was significantly higher than that of 50.8％(33/65)in patients without DM(x2 =5.689,P =0.017).Conclusion The average age was higher in breast cancer patients with Type 2 DM and most of them were in their menopausal status,furthermore the higher body mass index and worse prognosis were observed in this group,so the breast cancer patients with diabetes should choose the more reasonable treatment.
RESUMO
SIRT1 (Sirtuin type 1 ), a member of histone deacetylase, dependents on nicotinamide adenine dinucleotide ( NAD + ). It involves in the covalent modification of histones, participates in tumor development and progression through transcription, translation and post-translational modification and so on. Therefore, the expression of SIRT1 in tumor cells or abnormal function could be one of the important mechanisms of tumor development, and may become a new potential therapeutic target for neoplasms.
RESUMO
Objective To study the expression of S1RT1 in breast cancer with diabetes mellitus,and analyze the correlation between SIRT1 and p53,and analyze blood lipid differences in breast cancer tissue without diabetes mellitus and breast cancer tissue with diabetes mellitus,and to research its relation with type 2 diabetes mellitus and assesse the clinical value.Methods Immunohistochemistry was used to examine the expressions of SIRT1 and p53 in 30 breast cancer patients with diabetes mellitus and 30 breast cancer patients without diabetic mellitus,and their correlation was analyzed.Results The positive rate of SIRT1 in breast cancer tissue with diabetes mellitus was significantly lower than that in breast cancer tissue without diabetic mellitus(P ＜0.05).In SIRT1 positive tissue,the expression level of p53 was significantly higher than that in SIRT1 negative tissue(P ＜ 0.05 ).The expression of SIRT1 was significantly positively related with p53 expression in breast cancer tissue with diabetes( P ＜ 0.05).BMI and TG in breast cancer group with diabetes mellitus were significantly higher than those in breast cancer group without diabetic mellitus( P ＜ 0.05 ),but HDL was lower( P =0.05 ).However,CHO and LDL had no significant differences in both groups( P ＞0.05 ).Conclusions SIRT1 is up-regulated in breast cancer,but the posltive rate of SIRT1 in breast cancer tissue with diabetes mellitus is significantly lower than that in breast cancer tissue without diabetic,and is associated with the progression of diabetes mellitus.SIRT1 protein is significantly positively correlated to p53 expression and it may be involved in the adjustment process of blood lipids,SIRT1 might be a new biological target in diabetes and breast cancer.
RESUMO
Serum matrix metalloproteinase-9 (MMP-9)and advanced glycation end products (AGE)levels were measured in the diabetic patients with or without foot problems as well as in healthy retired people. In diabetic patients serum MMP-9 and AGE levels were significantly higher than those in healthy subjects. Median MMP-9 level in patients with diabetic foot was higher than that in diabetic patients without foot ulcers. Increased serum MMP-9 in diabetes might predict occurance of diabetic foot and poor wound healing of the foot ulcers.